This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Propensity-matched lesion-based comparison of midt...

Propensity-matched lesion-based comparison of midterm outcomes of TAXUS Express and TAXUS Libert� stents for de novo native coronary stenosis

Read time: 1 mins
Published:25th Mar 2020


We examined the implication of the revised platform of TAXUS Libert� (TAXUS-Lib; Boston Scientific, Natick, MA, USA) from TAXUS Express (TAXUS-Exp; Boston Scientific) stents, after stent placements in a daily practice environment, on midterm clinical and angiographic outcomes.

Methods and results:

By adjusting historically different baselines with propensity score matching analysis in 1358 de novo native coronary stenoses, the incidence of the clinical safety endpoint (700-day cardiac death, nonfatal recurrent myocardial infarction, and definite stent thrombosis) after placement of TAXUS-Lib (0.60%; mean follow-up, 683�64 days) was not significantly different from that in the TAXUS-Exp group (1.20%; 677�96 days, p=0.182). Cardiac dysfunction (ejection fraction of left ventricle less than 40%) was the predictor of primary endpoint [odds ratio (OR), 17.8; 95% CI, 4.39�71.9; p<0.001]. in the baseline-adjusted angiographic followed-up lesions (n="443" in each arm), the incidence of secondary endpoint [binary in-stent restenosis: percent diameter stenosis (%ds)>50% at the follow-up angiography] in the TAXUS-Lib group (11.3%) was not significantly different from that in the TAXUS-Exp group (13.5%, p=0.368). TAXUS-Exp was not the predictor of secondary endpoint (OR, 1.20; 95% CI, 0.77�1.85; p=0.424).


The midterm clinical and angiographic outcomes after placement of the new TAXUS-Lib stent for de novo coronary stenosis in a daily practice environment were statistically equivalent compared to the former TAXUS-Exp.

Read abstract on library site